PubMed

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M.

Diabetes. 2007 May;56(5):1475-80. Epub 2007 Feb 15.PMID: 17303799 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M.

Clin Endocrinol (Oxf). 2008 Nov;69(5):737-44. Epub 2008 Mar 10.PMID: 18331607 [PubMed - indexed for MEDLINE]Related articles

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA.

J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23.PMID: 17244786 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.PMID: 16912128 [PubMed - indexed for MEDLINE]Related articlesFree article

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE.

J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. Epub 2007 Nov 27.PMID: 18042650 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.

J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. Epub 2008 Oct 28.PMID: 18957505 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR.

Diabetologia. 2006 Sep;49(9):2049-57. Epub 2006 Jul 1.PMID: 16816950 [PubMed - indexed for MEDLINE]Related articles

Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients.

Gonlachanvit S, Hsu CW, Boden GH, Knight LC, Maurer AH, Fisher RS, Parkman HP.

Dig Dis Sci. 2003 Mar;48(3):488-97.PMID: 12757160 [PubMed - indexed for MEDLINE]Related articles

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.

Diabet Med. 2005 Apr;22(4):470-6.PMID: 15787675 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M.

Clin Pharmacokinet. 2007;46(7):577-88.PMID: 17596103 [PubMed - indexed for MEDLINE]Related articles

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

Diabetes Care. 1997 Dec;20(12):1874-9.PMID: 9405910 [PubMed - indexed for MEDLINE]Related articles

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.

Curr Med Res Opin. 2008 Oct;24(10):2943-52. Epub 2008 Sep 10.PMID: 18786299 [PubMed - indexed for MEDLINE]Related articles

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.

Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J.

J Clin Endocrinol Metab. 2009 Mar;94(3):846-52. Epub 2008 Dec 16.PMID: 19088168 [PubMed - indexed for MEDLINE]Related articles

Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.

He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE.

J Clin Pharmacol. 2007 May;47(5):633-41.PMID: 17442688 [PubMed - indexed for MEDLINE]Related articles

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.

Diabetes. 2004 May;53(5):1187-94.PMID: 15111485 [PubMed - indexed for MEDLINE]Related articlesFree article

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75.PMID: 19046215 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE.

J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94. Epub 2005 May 10.PMID: 15886245 [PubMed - indexed for MEDLINE]Related articlesFree article